CN104940994A - 一种人造鼻粘膜及其用途 - Google Patents
一种人造鼻粘膜及其用途 Download PDFInfo
- Publication number
- CN104940994A CN104940994A CN201510412461.4A CN201510412461A CN104940994A CN 104940994 A CN104940994 A CN 104940994A CN 201510412461 A CN201510412461 A CN 201510412461A CN 104940994 A CN104940994 A CN 104940994A
- Authority
- CN
- China
- Prior art keywords
- pyrrolidone
- acid
- group
- nasal mucosa
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002850 nasal mucosa Anatomy 0.000 title claims abstract description 59
- 229950008882 polysorbate Drugs 0.000 claims abstract description 63
- 229920000136 polysorbate Polymers 0.000 claims abstract description 63
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 38
- 238000002360 preparation method Methods 0.000 claims description 21
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 16
- 229910052700 potassium Inorganic materials 0.000 claims description 16
- 239000011591 potassium Substances 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- -1 pyrrolidone sodium carboxylate Chemical class 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical class OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- OWVLYQRCCIEOPF-QHTZZOMLSA-L zinc;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Zn+2].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]1CCC(=O)N1 OWVLYQRCCIEOPF-QHTZZOMLSA-L 0.000 claims description 9
- 239000003607 modifier Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 230000003204 osmotic effect Effects 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229960004308 acetylcysteine Drugs 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 229910052748 manganese Inorganic materials 0.000 claims description 3
- 239000011572 manganese Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 108010039918 Polylysine Proteins 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 229960005188 collagen Drugs 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920002643 polyglutamic acid Polymers 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 229940054269 sodium pyruvate Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003223 protective agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 241000712461 unidentified influenza virus Species 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 206010039085 Rhinitis allergic Diseases 0.000 abstract description 12
- 201000010105 allergic rhinitis Diseases 0.000 abstract description 12
- 230000035876 healing Effects 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 10
- 230000000474 nursing effect Effects 0.000 abstract description 2
- DHERNFAJQNHYBM-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1.O=C1CCCN1 DHERNFAJQNHYBM-UHFFFAOYSA-N 0.000 abstract 2
- 238000009395 breeding Methods 0.000 abstract 1
- 230000001488 breeding effect Effects 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 239000000017 hydrogel Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 72
- 210000004027 cell Anatomy 0.000 description 40
- 241000700605 Viruses Species 0.000 description 33
- 210000001331 nose Anatomy 0.000 description 24
- 238000011282 treatment Methods 0.000 description 18
- 210000004400 mucous membrane Anatomy 0.000 description 16
- 230000002980 postoperative effect Effects 0.000 description 14
- 210000003928 nasal cavity Anatomy 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 206010022000 influenza Diseases 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 206010039083 rhinitis Diseases 0.000 description 10
- 230000000840 anti-viral effect Effects 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 239000012679 serum free medium Substances 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- ZGXNJZTZWUFBES-UHFFFAOYSA-N N1C(CCC1C(=O)O)=O.[K] Chemical compound N1C(CCC1C(=O)O)=O.[K] ZGXNJZTZWUFBES-UHFFFAOYSA-N 0.000 description 4
- 108010019160 Pancreatin Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 229940055695 pancreatin Drugs 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 231100001274 therapeutic index Toxicity 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 208000037062 Polyps Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000002155 anti-virotic effect Effects 0.000 description 3
- 210000004081 cilia Anatomy 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 229960003088 loratadine Drugs 0.000 description 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 210000000253 proventriculus Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000013129 endoscopic sinus surgery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000029052 metamorphosis Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004691 chief cell of stomach Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 208000016366 nasal cavity polyp Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组名 | ICAM |
正常组 | 1132.50±112.23 |
模型组 | 2451.30±145.12 |
试验组1+病毒 | 2134.60±178.11 |
试验组2+病毒 | 2251.80±132.44 |
试验组3+病毒 | 1543.40±144.03 |
试验组4+病毒 | 1365.60±167.32 |
TNF-ɑ | 4522.30±181.91 |
试验组1+TNF-ɑ | 1212.40±145.34 |
试验组2+TNF-ɑ | 1321.40±121.61 |
试验组3+TNF-ɑ | 4340.20±198.21 |
试验组4+TNF-ɑ | 4410.30±145.41 |
0分 | 1分 | |
畏寒 | 无 | 有 |
自汗 | 无 | 有 |
乏力 | 无 | 有 |
纳呆 | 无 | 有 |
便溏 | 无 | 有 |
夜尿清长 | 无 | 有 |
耳鸣 | 无 | 有 |
组别 | n | 效果显著 | 有效 | 无效 | 总有效率 |
对照组 | 30 | 5 | 20 | 5 | 83.33% |
试验组1 | 50 | 4 | 38 | 8 | 84% |
试验组2 | 50 | 0 | 38 | 12 | 76% |
试验组3 | 50 | 7 | 36 | 7 | 86% |
试验组4 | 50 | 0 | 35 | 15 | 70% |
试验组5 | 50 | 0 | 40 | 10 | 80% |
组别 | N | 第一层次 | 第二层次 | 第三层次 | 第四层次 | 有效率 |
试验1组 | 102 | 31(30.4) | 69(67.6) | 2(2.0) | 0 | 98 |
试验2组 | 102 | 26(25.5) | 72(70.6) | 4(3.9) | 0 | 96.1 |
试验3组 | 102 | 6(5.9) | 72(70.6) | 24(23.5) | 0 | 76.5 |
试验4组 | 102 | 14(13.7) | 70(68.6) | 17(16.7) | 1(1) | 90.2 |
对照组 | 102 | 11(10.8) | 68(66.7) | 21(20.0) | 2(2.5) | 77.4 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510412461.4A CN104940994B (zh) | 2015-07-14 | 2015-07-14 | 一种人造鼻粘膜及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510412461.4A CN104940994B (zh) | 2015-07-14 | 2015-07-14 | 一种人造鼻粘膜及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104940994A true CN104940994A (zh) | 2015-09-30 |
CN104940994B CN104940994B (zh) | 2017-09-19 |
Family
ID=54156406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510412461.4A Active CN104940994B (zh) | 2015-07-14 | 2015-07-14 | 一种人造鼻粘膜及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104940994B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106727279A (zh) * | 2016-11-29 | 2017-05-31 | 江苏长泰药业有限公司 | 抗过敏和防空气中pm2.5的鼻用组合物及其制备方法和用途 |
CN107007823A (zh) * | 2017-03-21 | 2017-08-04 | 深圳市康思得蛋白质工程有限公司 | 一种用于治疗鼻炎的药物及其制备方法 |
CN107441559A (zh) * | 2016-05-30 | 2017-12-08 | 任汉学 | 一种多糖生物高渗鼻腔护理喷剂及其制备方法 |
CN107441560A (zh) * | 2016-05-30 | 2017-12-08 | 任汉学 | 一种多糖生物鼻腔护理喷剂及其制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1379836A (zh) * | 1999-10-19 | 2002-11-13 | 宝洁公司 | 含有对皮肤柔和的抗病毒剂的薄页纸制品 |
CN1726044A (zh) * | 2002-12-17 | 2006-01-25 | 纳斯泰克制药公司 | 用于增强y2受体结合肽的粘膜传递的组合物和方法及治疗和预防肥胖症的方法 |
CN1805729A (zh) * | 2003-04-16 | 2006-07-19 | 默克专利股份有限公司 | 鼻用药物制剂和使用方法 |
CN1984674A (zh) * | 2004-06-07 | 2007-06-20 | 纳斯泰克制药公司 | 不含蛋白质或多肽类稳定剂的干扰素β鼻内制剂 |
CN101396431A (zh) * | 2007-09-30 | 2009-04-01 | 童玉新 | 鼻通宁凝胶及其制备方法 |
CN102048784A (zh) * | 2009-11-10 | 2011-05-11 | 董根荣 | 治疗鼻炎的喷雾剂及其制备方法 |
CN102319209A (zh) * | 2003-04-16 | 2012-01-18 | 德医药有限合伙公司 | 鼻用药物制剂和使用方法 |
CN104667256A (zh) * | 2015-03-18 | 2015-06-03 | 江苏威克斯医疗科技有限公司 | 一种鼻腔粘膜纤毛护理冲洗液及其用途 |
-
2015
- 2015-07-14 CN CN201510412461.4A patent/CN104940994B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1379836A (zh) * | 1999-10-19 | 2002-11-13 | 宝洁公司 | 含有对皮肤柔和的抗病毒剂的薄页纸制品 |
CN1726044A (zh) * | 2002-12-17 | 2006-01-25 | 纳斯泰克制药公司 | 用于增强y2受体结合肽的粘膜传递的组合物和方法及治疗和预防肥胖症的方法 |
CN1805729A (zh) * | 2003-04-16 | 2006-07-19 | 默克专利股份有限公司 | 鼻用药物制剂和使用方法 |
CN102319209A (zh) * | 2003-04-16 | 2012-01-18 | 德医药有限合伙公司 | 鼻用药物制剂和使用方法 |
CN1984674A (zh) * | 2004-06-07 | 2007-06-20 | 纳斯泰克制药公司 | 不含蛋白质或多肽类稳定剂的干扰素β鼻内制剂 |
CN101396431A (zh) * | 2007-09-30 | 2009-04-01 | 童玉新 | 鼻通宁凝胶及其制备方法 |
CN102048784A (zh) * | 2009-11-10 | 2011-05-11 | 董根荣 | 治疗鼻炎的喷雾剂及其制备方法 |
CN104667256A (zh) * | 2015-03-18 | 2015-06-03 | 江苏威克斯医疗科技有限公司 | 一种鼻腔粘膜纤毛护理冲洗液及其用途 |
Non-Patent Citations (1)
Title |
---|
张幼林等: "聚山梨酯80对呋麻滴鼻液稳定性的影响", 《中国药师》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107441559A (zh) * | 2016-05-30 | 2017-12-08 | 任汉学 | 一种多糖生物高渗鼻腔护理喷剂及其制备方法 |
CN107441560A (zh) * | 2016-05-30 | 2017-12-08 | 任汉学 | 一种多糖生物鼻腔护理喷剂及其制备方法 |
CN106727279A (zh) * | 2016-11-29 | 2017-05-31 | 江苏长泰药业有限公司 | 抗过敏和防空气中pm2.5的鼻用组合物及其制备方法和用途 |
CN107007823A (zh) * | 2017-03-21 | 2017-08-04 | 深圳市康思得蛋白质工程有限公司 | 一种用于治疗鼻炎的药物及其制备方法 |
CN107007823B (zh) * | 2017-03-21 | 2020-07-14 | 深圳市康思得蛋白质工程有限公司 | 一种用于治疗鼻炎的药物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104940994B (zh) | 2017-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104940994A (zh) | 一种人造鼻粘膜及其用途 | |
CN106668832B (zh) | 一种多肽在制备治疗肠道病毒感染药物的应用 | |
KR20180033517A (ko) | 홍합 접착 단백질 제품, 및 점막 염증을 억제하기 위한 그것의 용도 | |
JPH08501068A (ja) | クリル酵素の新規な薬学的用法 | |
Ebbens et al. | The fungal debate: where do we stand today? | |
US20200268656A1 (en) | Nebulized Ethanol for Internal Disinfecting and Improvement | |
CN107899006A (zh) | 冲洗鼻腔的药物组合物及其制备方法 | |
CN108743776A (zh) | 一种用于鼻部疾病防治的冲洗粉 | |
WO2015082965A2 (en) | Novel chitosan nasal wash | |
CN105687021A (zh) | 防治脚癣的爽足粉 | |
WO2004103399A1 (fr) | Utilisation d'ulinastatine pour traiter le syndrome respiratoire aigu et composition pharmaceutique contenant ulinastatine | |
CN110876796B (zh) | 一种用于治疗痛风急性发作的中药组合物及其制备方法和应用 | |
US20120021060A1 (en) | Honey Compositions and Uses Thereof | |
CN106138537A (zh) | 一种治疗全身疼痛的中药制剂及其制备方法 | |
RU2798661C1 (ru) | Гомеопатическая фармацевтическая композиция для лечения острых и обострения хронических воспалительных заболеваний верхних и нижних дыхательных путей на основе природных компонентов растительного, животного и минерального происхождения и ее применение | |
CN104815151A (zh) | 一种治疗温燥伤肺型咳嗽的中药 | |
CN104940372A (zh) | 一种治疗急性结膜炎的外用药物及其制备方法 | |
CN108815498A (zh) | 一种治疗咽炎的药物组合物及其制备方法与应用 | |
ES2938574T3 (es) | Péptido para la prevención o el tratamiento de la COVID-19 | |
US20210346459A1 (en) | Application of Dalargin for the prevention of VRIs and prevention of the development of complications during VRIs | |
Kacker | Looking after local nasal and sinus mucosa in health, disease and after surgery | |
CN100496492C (zh) | 治疗慢性鼻窦炎的甲苯咪唑新剂型 | |
CN104983799A (zh) | 一种治疗成痈期肺痈的中药组合物 | |
CN103933207A (zh) | 一种治疗鼻部表现为首发症状的韦格纳肉芽肿病的药物及其制备方法 | |
CN104523575A (zh) | 一种盐酸羟苄唑眼用凝胶剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Han Wei Inventor after: Jiang Wenfeng Inventor after: Shi Min Inventor after: Yu Yaping Inventor before: Yu Yaping Inventor before: Shi Min |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240605 Address after: 411100 West side of the first floor, Building 9, Innovation and Entrepreneurship Center, No. 31 Dongfeng Road, Economic Development Zone, Heping Street, Xiangtan City, Hunan Province Patentee after: Hunan Weike Medical Technology Co.,Ltd. Country or region after: China Address before: On the west side of the fourth floor, No. 65, Building G58, east of Lujia Road, west of Tai Road, China Pharmaceutical City, Taizhou City, Jiangsu Province, 225300 Patentee before: JIANGSU WEIKESI MEDICAL SCIENCE & TECHNOLOGY CO.,LTD. Country or region before: China |